Kura Oncology KURA
NASDAQ KURA
$9.82 -0.06 (-0.56%)
As of: Oct 22, 2026 · 9:34 AM EDT

Kura Oncology (KURA) EBT Margin (2025 - 2026)

Updated

Kura Oncology (KURA) recorded EBT Margin of -327.31% in Q2 2026, up 105.20 percentage points from -432.51% a year earlier and up 74.14 percentage points from the prior quarter.

Analysis

Kura Oncology (KURA) EBT Margin (2025 - 2026) Analysis & Trends

On a TTM basis, Kura Oncology's EBT Margin came in at -384.19% as of Jun 30, 2026; for FY2025, it was -412.51%, down 93.36 percentage points from FY2024.

  • Across earlier years, EBT Margin came in at -319.15% in FY2024.
  • Per Business Quant, the preceding three quarters came in at -401.45% (Q1 2026), -466.82% (Q4 2025) and -357.19% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Eli Lilly 1,152.37 Bn 1,120.96 Bn 19.71 Bn 40.25%
2 Johnson & Johnson 628.86 Bn 547.39 Bn 17.26 Bn 26.66%
3 AbbVie 500.37 Bn 473.48 Bn 12.70 Bn 25.18%
4 Merck 374.01 Bn 328.39 Bn 12.21 Bn -4.11%
5 Novartis Ag 300.56 Bn 264.55 Bn 11.24 Bn 29.63%
6 Astrazeneca 263.92 Bn 237.60 Bn 12.86 Bn 18.19%
7 Amgen 238.37 Bn 193.77 Bn 7.24 Bn 27.53%
8 Gilead Sciences 192.21 Bn 166.40 Bn 6.22 Bn -131.41%
9 Pfizer 171.20 Bn 117.84 Bn 10.94 Bn -4.34%
10 Kura Oncology 873.00 Mn -1.44 Bn 20.63 Mn -327.31%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -327.31%
Mar 31, 2026 -401.45%
Dec 31, 2025 -466.82%
Sep 30, 2025 -357.19%
Jun 30, 2025 -432.51%
Mar 31, 2025 -405.46%
API Access

Kura Oncology EBT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt-margin&ticker=KURA&period=max&api_key=YOUR_API_KEY